3 completed, 2 not yet recruiting, 2 unknown. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Not yet recruiting 2, Unknown 2 |
Follow T2DM (Type 2 Diabetes Mellitus): new trials by email Literature Review of T2DM (Type 2 Diabetes Mellitus) trials Research Report on T2DM (Type 2 Diabetes Mellitus)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function DA-302168S - Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chendu DIAO Pharmaceutical Group CO., LTD. | 32 | 2026-10-22 | 2026-10-15 |
| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 28 | 2026-10-08 | 2026-04-06 |
| Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Unknown | Newsoara Biopharma Co., Ltd. | 16 | 2021-12-01 | 2022-05-11 |
| A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects HEC88473 injection, Placebo - Healthy Subjects, Obesity | Phase 1 | Completed | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | 164 | 2021-08-11 | 2023-07-17 |
| Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 CKD-501, D759, D150, CKD-393 0.5/100/1000 mg - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 26 | 2021-02-18 | 2021-01-12 |
| The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2 Treatment A, Treatment B, Treatment C - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Completed | AJU Pharm Co., Ltd. | 30 | 2020-07-02 | 2021-07-21 |
| Single Escalating Dose Study Of HSK7653 In Healthy Subjects HSK7653, Placebo - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 62 | 2018-05-08 | 2023-08-09 |
Diabetes Mellitus, Type 2 (7) · Obesity (2) · Overweight (1)
Diabetes Mellitus (7) · Endocrine System Diseases (7) · Glucose Metabolism Disorders (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Body Weight (2) · Nutrition Disorders (2) · Overnutrition (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Overweight (1)
chiglitazar (1) · lobeglitazone (1)
AJU Pharm Co., Ltd. (1) · Chendu DIAO Pharmaceutical Group CO., LTD. (1) · Chipscreen Biosciences, Ltd. (1) · Chong Kun Dang Pharmaceutical (1) · Dongguan HEC Biopharmaceutical R&D Co., Ltd. (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Newsoara Biopharma Co., Ltd. (1)
China (3) · South Korea (2)
Choon Ok Kim, M.D., Ph.D. (1) · Hongzhong Liu (1) · Min-gul Kim (1) · Yanhua Ding, Doctor (1)